Drug intelligence / Profile preview

4B12-05

Development stage: Preclinical
Lead developer: 4B Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

4B12-05 is an early-stage investigational **monoclonal antibody** reportedly being developed by **4B Technologies** for **Alzheimer's disease**. Publicly accessible drug-indexing sources identify it as a discovery-stage nervous-system program, but they do not provide a validated molecular target, detailed mechanism of action, clinical data, route of administration, or formulation details. Based on the available evidence, it appears to be a sponsor-specific preclinical therapeutic antibody program rather than an approved or clinically characterized medicine.

Beyond the preview

Go deeper on 4B12-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4B12-05.

Explore the full profile